|Friday, February 21|
|CS12 Graphics in Oncology Drug Development||
Fri, Feb 21, 1:30 PM - 3:00 PM
Graphical Exploration of Response to Anti-Cancer Medicines and Patient Characteristics (302773)*Jennifer Gauvin, GlaxoSmithKline
Keywords: anti-cancer medicine, oncology, clinical trial, categorical data
When developing a new anti-cancer medicine, we often seek to explore, graphically, relationships between the response to medicine and characteristics like demographics and disease characteristics, including chromosomal abnormalities. In early phase clinical trials, like first time in human studies, a very limited number of patients are exposed to the investigational drug, usually at different doses (until the optimal dose is defined). If the new medicine is a targeted therapy the patients enrolled on trial may be more homogeneous in disease characteristics. In general, however, first time in human trials do not restrict enrollment to a narrow patient population; samples sizes are small and heterogeneous.
In this talk we look at different graphical presentations of these data and highlight the pros/cons of each graph.